| 产品描述: | NMD670 is an orally active inhibitor of skeletal muscle specific chloride channel ClC-1 with an EC50 of 1.6 μM. NMD670 enhances neuromuscular transmission and improves muscle contraction and strength. NMD670 can be used in the study of muscle weakness and muscle fatigue. |
| 体外研究: |
NMD670 (20 mg/kg;口服;每日两次;两周) 在重症肌无力大鼠模型中具有改善作用。 |
| 体内研究: |
NMD670 (20 μM;20-30 分钟) 在重症肌无力大鼠离体肌肉纤维中可增加终板电位振幅,恢复动作电位兴奋,增强神经肌肉传递。 |
| 参考文献: |
1. Skov M, et al. The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis. Sci Transl Med. 2024 Mar 20;16(739):eadk9109. 2. Chin E, et al. Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial. Clin Pharmacol Ther. 2024 Dec 9. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.204 ml |
16.019 ml |
32.039 ml |
| 5 mM |
0.641 ml |
3.204 ml |
6.408 ml |
| 10 mM |
0.32 ml |
1.602 ml |
3.204 ml |
| 50 mM |
0.064 ml |
0.32 ml |
0.641 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |